|
End-of-day quote
Thailand S.E.
2026-08-18
|
5-day change | 1st Jan Change | ||
| 8.250 THB | +0.61% |
|
+1.23% | +13.01% |
| 08-17 | US High-Grade Bond Sales Set August Record as AI Spending Fuels Borrowing | MT |
| 08-17 | Wells Fargo Adjusts Price Target on AbbVie to $300 From $295, Keeps Overweight Rating | MT |
Company Valuation: AbbVie Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 239,371 | 285,707 | 273,605 | 314,021 | 403,830 | 442,362 | - | - |
| Change | - | 19.36% | -4.24% | 14.77% | 28.6% | 9.54% | - | - |
| Enterprise Value (EV) 1 | 306,225 | 339,749 | 320,176 | 375,610 | 463,570 | 502,853 | 494,024 | 482,738 |
| Change | - | 10.95% | -5.76% | 17.31% | 23.42% | 8.47% | -1.76% | -2.28% |
| P/E | 21x | 24.4x | 57x | 74.4x | 96.8x | 32x | 23.6x | 19.7x |
| PBR | 15.5x | 16.6x | 26.5x | 94.8x | -124x | -351x | 74.7x | 29.5x |
| PEG | - | 8.74x | -1x | -6.1x | -77.12x | 0x | 0.7x | 1x |
| Capitalization / Revenue | 4.27x | 4.92x | 5.04x | 5.57x | 6.6x | 6.55x | 6.02x | 5.6x |
| EV / Revenue | 5.46x | 5.85x | 5.89x | 6.67x | 7.58x | 7.44x | 6.72x | 6.11x |
| EV / EBITDA | 10.6x | 11x | 12.5x | 15.6x | 18.9x | 15.5x | 13.4x | 11.8x |
| EV / EBIT | 10.9x | 11.3x | 12.9x | 16.1x | 19.5x | 16.1x | 13.7x | 12.2x |
| EV / FCF | 13.9x | 14x | 14.5x | 21.1x | 26x | 20.3x | 13.3x | 13.2x |
| FCF Yield | 7.18% | 7.14% | 6.89% | 4.75% | 3.84% | 4.93% | 7.52% | 7.58% |
| Dividend per Share 2 | 5.31 | 5.71 | 5.99 | 6.29 | 6.65 | 6.857 | 7.208 | 7.562 |
| Rate of return | 3.92% | 3.53% | 3.87% | 3.54% | 2.91% | 2.74% | 2.88% | 3.02% |
| EPS 2 | 6.45 | 6.63 | 2.72 | 2.39 | 2.36 | 7.835 | 10.59 | 12.69 |
| Distribution rate | 82.3% | 86.1% | 220% | 263% | 282% | 87.5% | 68% | 59.6% |
| Net sales 1 | 56,122 | 58,054 | 54,318 | 56,334 | 61,160 | 67,585 | 73,520 | 79,063 |
| EBITDA 1 | 29,018 | 30,961 | 25,545 | 24,104 | 24,483 | 32,520 | 36,877 | 40,936 |
| EBIT 1 | 28,215 | 30,183 | 24,793 | 23,340 | 23,721 | 31,284 | 35,933 | 39,592 |
| Net income 1 | 11,542 | 11,836 | 4,863 | 4,278 | 4,226 | 13,862 | 18,914 | 22,010 |
| Net Debt 1 | 66,854 | 54,042 | 46,571 | 61,589 | 59,740 | 60,490 | 51,661 | 40,375 |
| Reference price 2 | 135.40 | 161.61 | 154.97 | 177.70 | 228.49 | 250.33 | 250.33 | 250.33 |
| Nbr of stocks (in thousands) | 1,767,880 | 1,767,880 | 1,765,537 | 1,767,140 | 1,767,385 | 1,767,117 | - | - |
| Announcement Date | 2/2/22 | 2/9/23 | 2/2/24 | 1/31/25 | 2/4/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 33.85x | 12.21x | 24.91x | 0.58% | 1,055B | |
| 29.18x | - | - | 2.05% | 632B | |
| 31.95x | 7.44x | 15.46x | 2.74% | 442B | |
| 19.84x | 4.71x | 11.68x | 2.81% | 351B | |
| 21.63x | 5.59x | 13.89x | 2.87% | 290B | |
| 20.07x | 4.15x | 11.78x | 2.12% | 243B | |
| 26.53x | 6.9x | 12.24x | 2.4% | 227B | |
| 13.3x | 4.74x | 9.93x | 3.86% | 200B | |
| -42.45x | 6.16x | 24.05x | 2.37% | 172B | |
| Average | 17.10x | 6.49x | 15.49x | 2.42% | 401.39B | |
| Weighted average by Cap. | 24.29x | 8.06x | 17.79x | 1.99% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ABBV Stock
- ABBV19 Stock
- Valuation AbbVie Inc.
Select your edition
All financial news and data tailored to specific country editions
